Insomnia is a problem for approximately 75% of people living with HIV, which is much higher
than the 6% to 10% of people with insomnia in the general population. It is currently unknown
why the rate of insomnia is so high among people living with HIV, and because of this, they
are often excluded from clinical trials examining the usefulness of cognitive behavioural
therapy for insomnia (CBT-I), which is recommended as the first-line treatment for insomnia.
Insomnia is also associated with poorer immune functioning and lower medication adherence.
The purpose of this study is to examine whether CBT-I is useful at reducing insomnia among
people living with HIV, and to examine whether this counselling is safe to provide to this
population. Other purposes are to explore whether reducing insomnia will lead to improved
immune functioning and medication adherence, to collect feedback about people's experiences
receiving CBT-I, to examine which psychological and behavioural factors are associated with
insomnia severity among people living with HIV.